Radiolabeled Monoclonal Antibodies for Imaging and Therapy

  • Suresh C. Srivastava

Part of the NATO ASI Series book series (NSSA, volume 152)

Table of contents

  1. Front Matter
    Pages i-xiv
  2. General: Monoclonal Antibody Production, Selection, and Characterization

    1. Front Matter
      Pages 1-1
    2. Peter D. Gorevic
      Pages 3-21
    3. A. A. Noujaim, B. M. Longenecker, M. R. Suresh, C. J. Turner, T. R. Sykes, G. D. MacLean
      Pages 23-38
    4. A. A. Noujaim, B. M. Longenecker, M. R. Suresh, G. D. MacLean, C. J. Turner, T. R. Sykes
      Pages 39-50
    5. S. Ferrone, M. Temponi, D. Gargiulo, G. A. Scassellati, R. Cavaliere, P. G. Natali
      Pages 55-73
    6. Richard P. McCabe, Leona C. Peters, Martin V. Haspel, Nicholas Pomato, Jorge A. Carrasquillo
      Pages 75-94
    7. Jean-Pierre Mach, Franz Buchegger, Angelika Bischof-Delaloye, Sven Curchod, Ariane Studer, Pelham Douglas et al.
      Pages 95-110
    8. S. J. DeNardo, G. L. DeNardo, S. V. Deshpande, G. P. Adams, D. J. Macey, S. L. Mills et al.
      Pages 111-122
    9. M. Lorenz, R. P. Baum, G. Herrmann, R. Inglis, M. Schulz
      Pages 123-128
    10. Catherine Larue, Corinne Chateigner, Patrick Gautier, Jacques Planchenault, Jocelyne Leger
      Pages 129-137
    11. Alexander Gottschalk, Eugene Cornelius, Paul B. Hoffer
      Pages 139-145
  3. Selection Criteria for Imaging and Therapy and the Production of Radionuclides

    1. Front Matter
      Pages 147-147
    2. Leonard F. Mausner, Rita F. Straub, Suresh C. Srivastava
      Pages 149-163
    3. S. James Adelstein, Amin I. Kassis
      Pages 165-176
    4. Keith Britton, Marie Granowska
      Pages 177-191
  4. Radiohalogenation and Radiometal Labeling of Monoclonal Antibodies

    1. Front Matter
      Pages 193-193
    2. Michael R. Zalutsky
      Pages 195-213
    3. James C. Reynolds, Patrick Maloney, Mark Rotman, Richard Fejka, Raymond A. Farkas, Kunihiko Yokoyama et al.
      Pages 215-227
    4. Chang H. Paik, William C. Eckelman, Richard C. Reba
      Pages 253-260
    5. Michael J. Welch, Michael R. Kilbourn
      Pages 261-267
  5. Immunoreactivity Considerations and In-vivo Pharmacokinetics of Labeled Monoclonal Antibodies

    1. Front Matter
      Pages 269-292
    2. Gerald L. DeNardo, Sally J. DeNardo, Daniel J. Macey, Stanley L. Mills
      Pages 293-310
    3. M. Granowska, K. E. Britton, M. Crowther, C. C. Nimmon, M. L. Slevin, J. Shepherd
      Pages 311-322
    4. Fyllis L. Otsuka, Michael J. Welch
      Pages 343-361
    5. David A. Goodwin
      Pages 363-375
    6. R. G. Melton, F. Searle, C. Bier, J. A. Boden, R. B. Pedley, A. J. Green et al.
      Pages 377-383
    7. Carlo Aprile, Raffaella Saponaro, Maurizio Villa
      Pages 385-390
  6. Radiobiologic and Dosimetric Considerations for Imaging and Therapy with Labeled Monoclonal Antibodies

    1. Front Matter
      Pages 391-391
    2. Steven Larson, Jorge Carrasquillo, James Reynolds, Andrew Keenan, Paul Sugarbaker, David Colcher et al.
      Pages 393-407
    3. Rodney E. Bigler, Pat B. Zanzonico, Michaela Cosma, George Sgouros
      Pages 409-429
  7. Instrumentation and Strategies for Radioimmunoimaging. Comparison with Other Imaging Modalities

  8. Radioimmunoimaging: Preclinical and Clinical Studies

About these proceedings


The advent of hybridoma technology leading to the successful produc­ tion of monoclonal antibodies against a variety of tumor-associated antigens has, during the last decade, provided a very powerful tool for research and clinical investigations. These highly specific reagents have essentially replaced the polysera of the earlier days. The successful demonstration of the many wide ranging capabilities of the monoclonal antibody technique has already begun to exert an enormous impact on diverse areas of research in basic science and medicine. In particular, the potential of monoclonal antibodies to serve as carriers for selective targeting of radionuclides to tumors for diagnosis or therapy, has stimulated an intense surge of research interest and even revived hopes of realizing Ehrlich's concept of the "magic bullet". Indeed, the technology appears to be on the threshold of a revolution in diagnosing and treating malignant disease. Much work remains to be done, however, and even though the progress has been impressive, results to date have shown only moderate success. There is no question that the limited success we have achieved thus far is merely a prelude to the many more exciting developments yet to come.


antibody antigen imaging

Editors and affiliations

  • Suresh C. Srivastava
    • 1
  1. 1.Brookhaven National LaboratoryUptonUSA

Bibliographic information